
    
      This is a phase II, open-label, multicenter, single-arm, prospective clinical study designed
      to investigate the efficacy and safety of Tislelizumab (anti-PD1 antibody) combined with
      carboplatin plus Nab-paclitaxel in Non-squamous NSCLC patients with EGFR sensitizing mutation
      who failed EGFR TKI therapy. The primary endpoint of the study is measured by 1-year PFS rate
      in efficacy analysis population.
    
  